Cenobamate Carbamate Combination Therapy Patent for Epilepsy Treatment
Summary
USPTO granted patent US12599585B2 to SK Biopharmaceuticals covering combination therapy using cenobamate [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate with antiepileptic drugs for preventing or treating neurological disorders such as epilepsy. The patent contains 5 claims and lists inventors Marc Kamin and Laurent Vernillet.
What changed
USPTO granted patent US12599585B2 to SK Biopharmaceuticals covering the use of cenobamate in combination therapy with antiepileptic drugs for epilepsy treatment. The patent protects combination formulations and methods using the carbamate compound with other therapeutic agents for neurological disorders.
For pharmaceutical manufacturers and patent holders, this grant establishes enforceable IP rights for cenobamate-based combination therapies in the US market. Competitors developing similar combination treatments will need to consider licensing or design-around strategies to avoid infringement on the granted claims.
What to do next
- Monitor patent portfolio for freedom-to-operate analysis
- Review licensing opportunities for combination therapy
Archived snapshot
Apr 14, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Use of [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate in combination therapy
Grant US12599585B2 Kind: B2 Apr 14, 2026
Assignee
SK BIOPHARMACEUTICALS CO., LTD.
Inventors
Marc Kamin, Laurent Vernillet
Abstract
The present disclosure provides combination therapy using [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate (cenobamate) and one or more antiepileptic drugs for the prevention or treatment of a neurological disorder such as epilepsy.
CPC Classifications
A61K 31/41 A61K 31/515 A61K 31/19 A61K 31/4015 A61K 31/4166 A61K 31/53 A61K 31/55 A61K 45/06 A61P 25/00 A61P 25/08
Filing Date
2023-04-13
Application No.
18134203
Claims
5
Named provisions
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.